Wockhardt Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt reported a strong standalone quarter with revenue from operations rising to ₹413 crore from ₹352 crore a year ago (about 17% growth), while standalone profit after tax jumped to ₹69 crore from just ₹6 crore in Q1 FY25, lifting EPS to ₹4.25. On a consolidated basis, however, revenue was flat at ₹738 crore and the company slipped into a loss of ₹108 crore, largely due to a one-time ₹97 crore exceptional charge. The exceptional item relates to an impairment of goodwill after Wockhardt decided to exit the US generic pharmaceutical business, filing for voluntary liquidation of its US step-down subsidiaries Morton Grove Pharmaceuticals Inc and Wockhardt USA LLC under Chapter 7 of the US Bankruptcy Code on July 11, 2025. The statutory auditors (MSKC & Associates) issued an unmodified limited review report on both standalone and consolidated results.
Standalone numbers show a sharp earnings recovery, which is positive for shareholders, but the consolidated loss — driven by the US business shutdown and ₹97 crore impairment — highlights that the drag from the generics business had been significant. Investors should focus on the standalone turnaround while monitoring how cleanly the US exit is executed, as the Chapter 7 liquidation may continue to impact near-term consolidated optics.